Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605449 | 0.92 | ALDH1A1 (0.48) | ALDH1A1POLBGAAMAOBPGR | |
| SCHEMBL143053 | 0.92 | MAOB (0.50) | ALDH1A1POLBGAAMAOBPGR | |
| SCHEMBL145108 | 0.90 | ALDH1A1 (0.47) | ALDH1A1POLBGAAMAOBPGR | |
| SCHEMBL6600745 | 0.89 | MAOB (0.48) | ALDH1A1POLBGAAMAOBPGR | |
| SCHEMBL146917 | 0.88 | ALDH1A1 (0.45) | ALDH1A1POLBGAAMAOBPGR | |
| SCHEMBL143369 | 0.86 | PDE4B (0.48) | ALDH1A1POLBGAAMAOBPDE4B | |
| SCHEMBL6605509 | 0.85 | ABL1 (0.50) | ALDH1A1POLBMAOBSMN1; SMN2LMNA | |
| SCHEMBL6362435 | 0.85 | ALDH1A1 (0.46) | ALDH1A1POLBGAAMAOBPGR | |
| SCHEMBL6601851 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBGAAMAOBPGR | |
| SCHEMBL7645940 | 0.85 | ALDH1A1 (0.46) | ALDH1A1POLBGAAMAOBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | claimed |
| EP-1463509-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | claimed |
| EP-1368035-A1 | USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES | MERCK PATENT GmbH (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2003037349-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2003-05-08 | — | — | WO | claimed |
| WO-2002072103-A1 | USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES | MERCK PATENT GMBH (DE) | 2002-09-19 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1463509-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2002072103-A1 | USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES | MERCK PATENT GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| EP-1143944-A3 | USE OF ARYLALKANOYLPYRIDAZINES | MERCK PATENT GmbH (DE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1143944-A2 | USE OF ARYLALKANOYLPYRIDAZINES | MERCK PATENT GmbH (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000059484-A2 | USE OF ARYLALKANOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2000-10-12 | — | — | WO | disclosed |
| US-6107295-A | Arylalkanoyl pyridazines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-22 | — | — | US | disclosed |
| EP-0922036-A1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GmbH (DE) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998006704-A1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | ALDH1A1 1103/4885POLB 4151/4885GAA 732/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | ALDH1A1 1103/4885POLB 4151/4885GAA 732/4885 |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | PDE4A, PDE4B, PDE12 | ALDH1A1 849/4885POLB 2262/4885GAA 482/4885 |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | PDE4A, PDE4B, PDE4C | ALDH1A1 762/4885POLB 2041/4885GAA 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.